Eupraxia Pharmaceuticals products

Our patented technology is designed to be tailored to a wide variety of drugs and therapeutic indications. In addition to our lead drug candidate (EP-104IAR), Eupraxia is currently developing an extended-release post-surgical anesthetic (EP-105) and antibiotic (EP-201). Eupraxia hopes to add 1-2 additional candidates to our pipeline within the next year, including an internally developed oncology product.

Many drugs have the potential to work well but are limited by the way they are delivered. This can lead to unwanted side effects, poor efficacy and a short duration of action. Eupraxia’s polymer-based proprietary technology aims to provide better therapy by delivering the right dose of drug, in the right place and for the right amount of time.

Eupraxia’s lead product candidate, EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA).